Colorectal cancer (CRC) is a malignant cancer with high incidence and mortality in the 24 world, as the result of the traditional treatments. Immunotherapy targeting neoantigens 25 can induce durable tumor regression in cancer patients, but is almost limited to 26 individual treatment, resulting from the unique neoantigens. Many shared oncogenic 27 mutations are detected, but whether the common neoantigens can be identified in CRC 28 is unknown. Using the somatic mutations data from 321 CRC patients combined with 29 a filter standard and 7 predicted algorithms, we screened and obtained 25 HLA-30 A*11:01 restricted common neoantigens with high binding affinity (IC50<50 nM) and 31 presentation score (EPIC>0.9). Except the positive epitope KRAS_G12V8-16, 11 out of 32 25 common neoantigens were proved to be naturally processed and presented on 33 constructed K562 cell surface by mass spectroscopy (MS), and 11 out of 25 common 34 neoantigens specifically induced in vitro pre-stimulated cytotoxic lymphocyte (CTL) 35 to secrete IFN-. However, only 2 out of 25 common neoantigens were simultaneously 36 presented and immunogenic. Moreover, using cell-sorting technology combined with 37 single-cell RNA sequencing, the immune repertoire profiles of C1orf170_S418G413-421 38 and KRAS_G12V8-16-specific CTL were clarified. Therefore, common neoantigens 39 with presentation and immunogenicity could be found in CRC, which would be 40 developed as the universal targets for CRC immunotherapy. 41 42 43 44 45 46 Colorectal cancer (CRC) is the third commonest diagnosed malignant cancer and 47 the second leading cause of cancer death in the world [1]. In 2018, more than 1.8 48 million new cases of CRC and almost 881 thousand cases of CRC-interrelated death 49 occurred in the world [1], and the global burden of CRC is estimated to reach over 2.2 50 million new cases and 1.1 million cancer deaths by 2030 [2]. Traditionally surgical 51 resection can cure the early stage of CRC, but about 50% of patients ultimately die of 52 distant metastases. While chemotherapy, radiation therapy and targeted therapy can 53 extend overall survival, less than 15% of patients with metastatic CRC survive 54 beyond 5 years [3]. Therefore, the novel and more effective therapeutic approaches 55 for CRC are necessary to develop. 56 In the recent years, based on a better knowledge of the complex interactions 57 between the immune system and the tumor microenvironment, immunotherapy has 58 become a novel effective and promising therapeutic strategy for cancer, and its 59 efficacy was widely tested by CRC model. The vast majority of CRC patients with 60 deficient mismatch repair (dMMR) or highly microsatellite instable (MSI-H) benefit 61 from immune checkpoint inhibitors, which is not effective in other CRC patients with 62 proficient MMR (pMMR) or microsatellite stable (MSS) [4]. Patients with CRC do 63 not respond to autologous tumour lysate DC (ADC) and peptide vaccines [4]. T cells, 64 which are engineered to express an affinity-enhanced T-cell receptor (TCR) or an 65 antibody-based chimeric antigen receptor (CAR) targeting tumor associated antigens 66 (TAAs), such as carcinoembryonic antigen (CEA) [5, 6] and human epidermal growth 67 factor receptor-2 (HER2) [7], regress metastatic CRC, but simultaneously mediate 68 severe autoimmunity in patients. These results highlight the importance of identifying 69 tumor specific antigens, which optimally discriminate tumor and normal tissues, for 70 improving the efficacy and safety of adoptive T-cell therapy for CRC. 71 Compared with TAAs, which lowly express in some normal cells but 72 overexpress in tumor cells [5-7], mutated tumor-specific antigens (TSAs) arise from 73 the somatic mutations in protein-coding regions of tumor cells, and are exclusively 74 4 present in malignant cells and not produced by normal tissues [8]. The accumulated 75 mutations in cancers include nonsynonymous, nonsense, indel and frame shift, and are 76 classified into driver mutations, which involve in uncontrolled cell growth and tumor 77 metastasis, and passenger mutations, which may not contribute to the tumorigenic 78 phenotype, but increase immunogenicity [9]. Through the antigen presentation 79 system, peptides, which contain the mutant site and are called neoantigens, can be 80 presented on the surface of tumor cells by major histocompatibility complex (MHC) 81 molecules, then recognized by T cells to lead robust anti-metastatic CRC activity [10]. 82 Furthermore, T-cell responses elicited by neoantigens are not subject to host central 83 tolerance in the thymus and also bring fewer toxicities deriving from autoimmune 84 reactions to normal cells [11]. The highly individual neoantigens actualize the 85 personalized cancer immunotherapies, but limited the development of "one fits all" 86 pharmacologic solutions [11]. 87 It has been shown that some cancers with high tumor mutational burden (TMB) 88 possess a set of common neoantigens owing to the microsatellites [11]. The presence 89 of microsatellite instability has been found in approximately 15-20% CRC, and 90 dMMR CRC has a high TMB, which is far higher than the standard value [4]. 91 Furthermore, driver mutations possess only 8% CD8 T-cell neo-epitopes, while 92 passenger mutations possess 92% CD8 T-cell neo-epitopes and 100% CD4 T-cell 93 neo-epitopes [9]. HLA-A*11:01 allele has high prevalence in US Caucasians, Asian-94 Americans and China [12] (http://www.allelefrequencies.net/). Therefore, we 95 hypothesized that targeting the common neoantigens, comprising driver mutations and 96 passenger mutations and restricted by HLA-A*11:01, not only improved the efficacy, 97 safety and adoption of CRC immunotherapy, but also reduced the cost and time of 98 CRC clinical treatment. In the present study, we predicted the HLA-A*11:01 99 restricted common neoantigens from the somatic mutations data of 321 patients with 100 CRC and validated their presentation and immunogenicity, which would become the 101 new targets for CRC immunotherapy.
Introduction
extracted peptides, in which the results were shown by the scores of highest 144 presentation probability. These mutant peptides with strong binding capacity and high 145 score of presentation probability were selected as potential neoantigens.
147
The construction of putative neoantigens transduced K562 cells (HLA-A*11:01 + ) 148 Six predicted neoantigens were linked into a tandem neoantigen as previously 149 described [21] . Briefly, six predicted neoantigens, which each had 27 amino acids 150 with the mutation at position 14, were connected by a start linker (GGSGGGGSGG), Technologies Ltd, Wuhan, China). Lentiviral particles encoding tandem minigenes 160 were produced from HEK-293 cells, which were simultaneously transduced with 161 packaging constructs (RRE, REV and VSVG (invitrogen)) and the expressing vector, 162 and infected mono HLA-A*11:01 allelic K562 cells. Positive K562 cells were 163 selected by Blasticidine S hydrochloride (5 g/ml, Sigma) and detected through the 164 percentage of reporter gene ZsGreen.
166
The preparation of MHC Class I bound peptides 167 MHC-I peptidomes were obtained from mono HLA-A*11:01 allelic K562 cells 168 transduced with putative neoantigens as described previously [22] . In brief, 1×10 9 169 cells were dissociated using lysis buffer (0.25% sodium deoxycholate, 1% n-octyl 170 glucoside, 100 mM PMSF and protease inhibitors cocktail in phosphate buffer saline 171 (PBS)) at 4 ℃ for 60 min. Lysate were further cleared by centrifugation at 14,000 g 172 for 30 min. Cleared lysate were purified with pan-HLA class I complexes antibody 173 (clone W6/32) covalently bound Protein-A Sepharose CL-4B beads (GE Healthcare). 174 Beads were washed with Tris-HCl buffer containing NaCl. The MHC-I molecules 175 were eluted at room temperature using 0.1 N acetic acid. Eluate was loaded on Sep- 183 Peptides were separated by a nanoflow HPLC (15 cm long, 75 m inner diameter 184 column with ReproSil-Pur C18-AQ 1.9 m resin) and coupled on-line to a Fusion Table 1 -6). Full scan MS spectra were acquired at a resolution of 6,000 190 at 350-1,400 m/z with a target value of 4×10 5 ions. MS/MS resolution was 60,000 at 150-2,000 m/z, and higher collisional dissociation (HCD) was employed for ion 192 fragmentation. The interpretation of MS data was performed with Skyline. To validate 193 a peptide which could be presented by MHC-I complex, the following criteria were 194 considered: i) the variation of retention time between precursor ions was less than 3 195 min; ii) the pattern and retention time were matched between synthetic peptide and 196 target peptide for no less than 5 product ions.
Peptide validation by mass spectroscopy (MS) analysis with PRM

198
The preparation of tetramer of peptide-MHC complex 199 Peptides (Table 1) and HLA-A*11:01-restricted KRAS G12V8-16 200 (VVGAVGVGK) as positive peptide were synthesized from GenScript (Nanjing,
201
China), with purity greater than 98% by mass spectroscopy. Peptide-MHC tetramers 202 were generated as previously described [23] . In briefly, Peptides (400 M) were 203 mixed with Flex-T™ HLA-A*11:01 Monomer UVX (Biolegend), then subjected to 204 UV light for 30 min on ice. The MHC monomers exchanged with peptides were 205 tetramerized in the presence of allophycocyanin (APC) conjugated streptavidin (BD 206 Biosciences) for 30 min at 37 °C , then the reaction was stopped by PBS containing D-207 Biotin (500 M) and NaN3 (10%), then kept at 4 °C overnight for use.
209
The generation of mature dendritic cells (mDCs) 210 Monocytes (CD14 positive) were positively selected using CD14 MicroBeads 211 (Miltenyi Biotec) from PBMCs of healthy donors as the manufacturer's protocol, and 212 cultured in CellGenix TM DC media (CellGenix) supplemented with 2% human serum 213 albumin (HSA, CSL Behring L.L.C.), granulocyte-macrophage colony stimulating 214 factor (GM-CSF, 100 ng/ml; PeproTech) and interleukin 4 (IL-4, 100 ng/ml; 215 PeproTech) for 5 days. On day 6, immature DCs were stimulated to mature by TNF-216  (10 ng/ml; PeproTech), IL-6 (50 ng/ml; PeproTech), IL-1 (10 ng/ml; PeproTech),
217
Prostaglandin E2 (500 ng/ml; Sigma) and Poly(I:C) (10 g/ml; InvivoGen) for 2 days.
218
After harvest, mDCs were pulsed with peptides (1 g/ml, Table 1 ) in FBS-free RPMI-219 1640 medium for 4 hours at 37 °C , and used as the antigen presented cells. The 220 maturity of DC was determined through the morphology and the phenotype of the expressions of CD80, CD83, CD86, CD11c and HLA-DR.
223
The induction of neoantigen-specific cytotoxic lymphocyte (CTL) 224 CD8 + T cells were positively enriched using CD8 MicroBeads (Miltenyi Biotec) 225 from PBMCs of healthy donors as the manufacturer's protocol, stimulated by mDCs 226 pre-loaded with peptides at a 4:1 ratio, and maintained in HIPP™-T009 medium 227 (Bioengine) in the presence of 2% autoserum and IL-21 (30 ng/ml, PeproTech) in a 228 37°C 5% CO2 incubator for 12 days. On day3, the co-culture system was supplemented 229 with IL-2 (5 ng/ml, PeproTech), IL-7 (10 ng/ml, PeproTech) and IL-15 (10 ng/ml, 230 PeproTech), which were repeated every 2-3 days. After 12-day culture, the pre-231 stimulated CD8 + T cells were re-stimulated with same peptide-pulsed mDCs as above 232 and incubated for another 12 days. 
Results
277
The selection of mutant candidate peptides 278 In order to analyze the potential common neoantigens of CRC in China, which derived from driver mutations or passenger mutations, we ultimately collected 3,500 280 SNVs, of which the frequency was over 5 out of 321 patients, and 191 InDels, of 281 which the frequency was over 2 out of 321 patients, from the somatic mutations data 282 of 321 CRC patients from COCA-CN in ICGC database on August 29, 2018. Both 9-283 10-mer mutant epitope candidates and reference peptides were extracted from 19 284 amino acids length, with 9 amino acids upstream and 9 amino acids downstream of 285 the 3,691 mutant sites. A total of 60,169 epitopes of SNV and 6,891 epitopes of Indels 286 were generated and predicted the binding affinity with HLA-A*11:01 allele, by 287 NetMHC-4.0, NetMHCpan-3.0, NetMHCpan-4.0, PSSMHCpan-1.0, PickPocket-1.0 288 and SMM simultaneously. As a result, 56 mutant epitopes were selected as the IC50 289 value of predicted binders was less than 50 nM by at least three software packages, 290 and the smallest affinity predicted value during three softwares was taken as the 291 affinity predicted score of the peptide-MHC complex (Table 1 and data not shown).
292
Furthermore, the algorithm EPIC, which was an effective, flexible and publicly 293 available HLA-I presented epitope prediction method, was used to evaluate the 294 probability of presentation of 56 mutant epitopes with strong binding affinity. The
295
EPIC score value of 25 out of 56 mutant epitopes was more than 0.9, which meant 296 that the probability of predicted epitope being presented by MHC was absolutely high 297 (Table 1 ). Finally, 25 mutant epitopes related to 25 somatic mutations of 21 genes 298 were selected as peptide candidates, and assessed their presentation and 299 immunogenicity (Table 1) . Moreover, during the 21 genes, we found that RNF43 gene 300 was a tumor suppressor gene, CTNNB1 gene was an oncogene, and the remaining 301 genes had not been identified as tumor-associated genes, which also encoded potential 302 neoantigens by CRC, in Cancer Gene Census database 303 (https://cancer.sanger.ac.uk/census) (Table 1) .
305
The expression of predicted peptides from constructed K562 cells 306 T cells attacking targeted cells mainly depends on that TCR recognize T-cell 307 epitopes, which are expressed, naturally processed and presented by MHC molecules 308 on the cell surface [24] . In order to improve the probability of the predicted epitopes 309 being presented by MHC class I, the predicted peptides were linked into the tandem 310 minigenes, and fused with N-terminal leader peptide and C-terminal MITD, which 311 have been proved to strongly improve the presentation of MHC class I and class II 335 by MS 336 In order to verify the predicted epitopes could be naturally processed and 337 presented by cells, we employed an immunoproteomics approach to enrich the 338 immunopeptidome of constructed K562 cells with mono HLA-A*11:01 allele. In this 339 approach, MHC-I restricted peptides were isolated and analyzed with MS. Targeted 340 MS assays with PRM were developed and characterized using stringent search 341 criteria, and resulted in 12 epitopes, including KRAS_G12V8-16, GLCE_V533I526-535, 
The identification of MHC Class I presented epitopes from constructed K562 cells
378
The number of spot mediating by the remainder peptides almost equated that of the 379 negative control, which signified that those peptides did not stimulate CTL to express Single-Cell Immune Profiling Solution to determine T-cell receptor repertoires.
398
For T-cell receptor repertoires recognizing HLA-A*11:01 presented 399 C1orf170_S418G413-421, a total of 9,243 cells (exactly GEM) were finally estimated 400 from 17,800 sorted cells, and 14,042 TCR  chain and 9,346 TCR  chain amino acid 401 sequences were respectively obtained, of which 8,826 pairs of TCR were produced.
402
TCR repertoire was preferentially biased toward usage of TRAV29DV5 gene 403 (55.38%) and TRAV35 gene (37.35%) ( Figure 6(a) ), which corresponding mainly 404 rearranged with TRAJ54 (99.88%) and TRAJ29 ( Figure 6(b) , and data not shown).
405
The length distribution of CDR3 was preferentially restricted to 12 mer (55.64%) 406 and 15 mer (39.09%) ( Figure 6(c) ), and the motif of 12-mer and 15-mer CDR3 was 407 respectively highly conserved as CAASGGAQKLVF ( Figure 6 (Table 3) .
420
For T-cell receptor repertoires recognizing HLA-A*11:01 presented 421 KRAS_G12V8-16, a total of 12,530 cells (exactly GEM) were finally estimated from 422 21,000 sorted cells, and 11,137 TCR  chain and 13,126 TCR  chain amino acid 423 sequences were respectively obtained, of which 10,559 pairs of TCR were produced.
424
TCR and  repertoires respectively used immunodominant TRAV8-3 gene (81.69%) 425 (Figure 7(a) ), which mainly rearranged with TRAJ20 (99.69%) (Figure 7(b) ), and 426 TRBV11-2 gene (83.35%) (Figure 7(d) ), which mainly rearranged with TRBJ2-7 427 (99.81%) (Figure 7(e) ). The length distribution of CDR3 and CDR3 was 428 respectively highly restricted to 10 mer (81.88%) (Figure 7(c) ) and 14 mer (86.4%) 429 (Figure 7(f) ). The motif of 10-mer CDR3 and 14-mer CDR3 was respectively 430 conserved as CASNDYKLSF (Figure 7(g) ), which was consistent with that of 431 TRAV8-3-TRAJ20, and CASSLDGVSYEQYF (Figure 7(h) ), which was consistent 432 with that of TRBV11-2-TRBJ2-7. There were 1,610 diversities in the 10,559 433 TCR/TCR pairs, but two clones accounted for a large proportion in the repertoire. containing TCR but were not detected TCR (Table 3 ). Our results revealed that the 438 dominant clone represented the usage genes and the CDR3 motifs of the TCR 439 repertoire.
440
The data that support the findings of this study have been deposited in the CNSA 441 (https://db.cngb.org/cnsa/) of CNGBdb with accession code CNP0000518. PSSMHCpan-1.0, PickPocket-1.0 and SMM, and EPIC algorithm that predicted 484 epitope presentation to evaluate the extracted peptides. Finally, we selected 25 485 candidate peptides, which simultaneously met the conditions of the frequency of SNV 486 being over 5 out of 321 patients and InDel being over 2 out of 321 patients, IC50 487 value being less than 50 nM by at least three software packages and EPIC score value 488 being more than 0.9 (Table 1) , to assay their characteristics of presentation and 489 inducing cytotoxic T cells. We found that 11 out of 25 (44%) predicted epitopes were 490 proved to be presented by HLA-A*11:01 allele through MS (Figure 2) , and 11 out of (Figure 1(a) ), were constructed and transfected into HLA-A*11:01 mono-513 allelic K562 cells. We found that over 85% HLA-A*11:01 mono-allelic K562 cells 514 highly expressed the tandem minigenes (Figure 1(b) ), and used 1×10 9 cells to extract 515 and purify the peptides, which were followed by analysis with a mass spectrometer. 516 Finally, except the positive epitope (KRAS_G12V8-16), we confirmed that 11 out of 517 25 predicted neoantigens were naturally processed and presented by HLA-A*11:01 518 allele, in which the positive rate was up to 44% (11/25) ( Figure 2) . However, the 519 remaining neo-peptides were not detected in our system. Recently, Muhammad Ali et 520 al. proved that minimizing the formation of irrelevant immunogenic peptides could 521 increase the targeted epitopes to bind HLA, and the order of arranged epitopes in the 522 tandem minigene were involved in the efficiency of antigen presentation [26] . In our 523 present study, the predicted neoantigens in the tandem minigene each had 27 amino 524 acids with the mutation at position 14 (Table 2) , which may result in the formation of 525 other high-affinity irrelevant and competitive presented peptides, and were randomly 526 combined in the tandem minigene. Therefore, we considered that the proper length 527 and the appropriate order of desired neoantigens in the tandem minigene may improve 528 the probability of the remaining neo-peptides being detected by MS.
529
The immunogenicity of predicted neoantigens is usually detected through the 530 response of TIL [11, 12] . Moreover, although the frequency of the neoantigen-531 reactive T cells in the peripheral blood is quiet low compared with that in the tumor 532 sample, neoantigen-specific T cells, which derive from circulating CD8 + memory T 533 cells of cancer patients or circulating CD8 + naï ve T cells of healthy donors, can be 534 enriched after being in vitro co-cultured with the cognate DCs pre-loaded 535 neoantigens, and their response to recognize the corresponding neoantigens can be 536 detected by conventional experimental methods [12, 26, 41] . Therefore, we generally 537 adopted one of the proven methods to detect the immunogenicity of our predicted 538 neoantigens, in which the circulating bulk CD8 + T cells from one healthy donor were 539 stimulated for two rounds by cognate DCs pre-loaded neoantigens. Except the 540 positive epitope (KRAS_G12V8-16), we found 11 out of 25 (44%) predicted 541 neoantigens that were pre-loaded on T2 cells could induce co-cultured CTL to secrete 542 IFN- (Figure 4) , and the frequencies of the specific CTL, that produced over 10 folds 543 IFN- spots than the negative control, were estimated to range between 0.22% and 544 7.08% (Figure 5(a) ). However, most of the presented neoantigens were not detected to 545 be immunogenic in our study. As approximately only one in 10 5 -10 6 T cells is specific 546 for a given antigen in the lymph node, and circulating CD8 + memory T cells from 547 healthy donors do not contribute to the production of neoantigen-responsive T cells, 
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The pie charts showed the top 9 usage genes, and the remaining usage genes were 
